Apeiron initiates clinical study to investigate prevention of radiation- induced skin damage in breast cancer patients

APEIRON Biologics AG (Apeiron) today announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients.

Press release

Presseaussendung